Purpose With the ever-increasing cure rates in breast cancer, radiotherapy-induced cancers have become an important issue. This study aimed to estimate secondary cancer risks for different treatment techniques, taking into account organs throughout the body. Material and methods Organ doses were evaluated for a tangential three-dimensional conformal (3D-CRT) and a multi-field intensity-modulated radiotherapy (IMRT) plan using a validated, Monte Carlo-based treatment planning system. Effects of wedges and of forward versus inverse planning were systematically investigated on the basis of phantom measurements. Organ-specific cancer risks were estimated using risk coefficients derived from radiotherapy patients or from the atomic bomb survivors. Results In the 3D-CRT plan, mean organ doses could be kept below 1 Gy for more remote organs than the lung, heart, and contralateral breast, and decreased to a few cGy for organs in the lower torso. Multi-field IMRT led to considerably higher mean doses in organs at risk, the difference being higher than 50% for many organs. Likewise, the peripheral radiation burden was increased by external wedges. No difference was observed for forward versus inverse planning. Despite the lower doses, the total estimated secondary cancer risk in more remote organs was comparable to that in the lung or the contralateral breast. For multi-field IMRT it was 75% higher than for 3D-CRT without external wedges. Conclusion Remote organs are important for assessment of radiation-induced cancer risk. Remote doses can be reduced effectively by application of a tangential field configuration and a linear accelerator set-up with low head scatter radiation. Schlüsselwörter Brustkrebs · Strahlenrisiko · Periphere Dosis · Risikomodelle · IMRT · 3D-CRT
Introduction
Breast cancer (BC) is the most common cancer in women with an age-standardized incidence rate of about 90 per 100,000 women in Western Europe [1] . In the past few decades, the life expectancy of BC patients increased substantially thanks to screening-related earlier detection and advances in treatment. The 5-year net survival is already above 85% in many countries [2] . Radiotherapy is part of the standard treatment after breast-conserving surgery for invasive tumours [3] , and possible late side effects are thus of increasing relevance. While studies on BC patients have shown that radiotherapy elevates the risks for cancers in organs close to the irradiation fields and for cardiac diseases [3, 4] , there are still important open questions related to the effect of contemporary radiotherapy techniques on cardiac diseases, to individual differences in risks, and to the impact of out-of-field exposure on secondary cancer risk. The German PASSOS project [5] addressed all of these issues, and some results on heart exposure and cardiac risk have been published [6] [7] [8] [9] . The present manuscript focuses on the assessment of doses and cancer risks in organs more remote to the treated breast than the lung, heart or contralateral breast. Possible cancer risks in these more remote organs have become increasingly important in the past years as the improvement of target coverage and the reduction of the high-dose volumes that can be achieved with modern multi-field techniques are always at the cost of a higher "low-dose bath". Doses to some remote organs for different radiation techniques in BC radiotherapy have been published by several authors [10] [11] [12] [13] [14] . However, dose estimates differ greatly between publications. Only in one publication [11] was an exhaustive number of organs considered. Additionally, there is a huge spread in risk estimates [15] owing to the application of various risk models, of which many were compiled for general radiation protection purposes and not for BC patients. Therefore, the aim of the present study was to complement and extend previous studies on remote organ doses and to provide realistic estimates of the radiationinduced cancer risks.
Materials and methods
To achieve these aims, we proceeded in several steps, which we will describe in detail. First, we estimated organ doses for a tangential three-dimensional conformal radiotherapy (3D-CRT) and a multi-field intensity-modulated radiotherapy (IMRT) technique with a Monte Carlo-based treatment planning system. Second, based on these doses, radiationinduced cancer risks were calculated. Calculations employ dose-response studies of BC radiotherapy for organs close to the fields, i. e. the lung, contralateral breast and oesoph-agus. For more remote organs, for which the low doses and associated effects hinder dose-response studies in BC patients, we applied results from the atomic bomb survivors of Hiroshima and Nagasaki. Finally, the variability in doses from different tangential techniques and in different individuals was investigated.
Organ dose assessment
Tangential and multi-field techniques lead to rather different dose distributions in the body. These differences were investigated by treatment plan calculations of a field-in-field 3D-CRT and a step-and-shoot multi-field IMRT plan. Both techniques were planned with flattening filters and without wedges, using 6-MV photon beams. The prescribed dose to the whole breast was 50.4 Gy plus an additional boost of 16 Gy to the tumour bed. Objectives were the minimization of exposure of the contralateral breast, ipsilateral lung and heart while keeping the dose within the planning target volume (PTV) between 95 and 107% of the prescribed dose. For small volumes within the PTV, maximum doses of up to 110% of the prescribed dose were accepted. The treatment fields for multi-field IMRT were based on the field direction of the respective 3D-CRT plan, with four different fields from each tangential direction (each separated by 10°). Additional four to eight fields were added, each separated by 40°, omitting fields that comprise the contralateral mammilla or that irradiate the contralateral lung before reaching the PTV. The resulting dose distributions are depicted in Figs. S1 and S2 in the supplementary material.
Breast cancer radiotherapy is usually planned based on a computed tomography (CT) scan of the patient's thorax. To calculate the exposure for more remote organs, it was necessary to create the plans on a whole-body CT scan that was obtained in connection with positron emission tomography from a female patient with cancer in the left lung. During CT, the patient was in supine position, similar to BC radiotherapy (see Fig. S3 in the supplementary material). At a height of 163 cm, the patient was close to the European average [16] and had a normal weight of 55 kg. The whole-body CT covered a cranio-caudal distance of about 103 cm and thus included the entire torso and head, the upper arms, and parts of the thighs. The contouring of the organs was conducted by a medical physicist and a medical doctor without using any auto-contouring features within the treatment planning system. To investigate the dosimetric differences between treatments of left-and right-sided breast tumours, treatment plans for both sides were created with similar gantry angles for both whole-breast and boostvolume on each side. For the planning, IPLAN 4.5.4 was applied, commissioned for a Vero accelerator (BrainLAB AG, Feldkirchen, Germany). IPLAN uses Pencil Beam for the optimization process and the Voxel Monte Carlo algorithm [17] for the final dose calculation. The Monte Carlo calculation is based on the analytical energy profile of the accelerator head modified by the multi-leaf collimator shaping the individual photon beam, which allows for a fast dose calculation [18, 19] . The accuracy of the dose calculation was validated by phantom measurements with a single 10 × 10 cm 2 open field and showed consistency within about 30% even for distances up to 40 cm from the irradiated area (see Figs. S4, S5 and S6 in the supplementary material).
Estimating cancer risks
Cancer risks were derived by applying published, organspecific risk models. For the organs not delineated in the CT, mean doses were estimated from the dose-volume histograms of nearby organs. This is a rather crude approach, but acceptable in view of the large dose uncertainty and variability. Details can be found in Table S1 in the supplementary material.
Studies on cancer risk in the lung [20] , contralateral breast [21] and oesophagus [22] after BC radiotherapy were applied in this work. The respective publications are tabulated together with best estimates of risk coefficients in Table S2 in the supplementary material. Here we treat odds ratios as equivalent to relative risks since the investigated diseases are rare. Risk coefficients for other solid cancer sites were based on a study of atomic bomb survivors [23] , evaluated for an age at exposure of 50 years and an attained age of 70 years, tabulated in Table S3 in the supplementary material. To calculate average relative risks for several cancer endpoints combined, the radiation-induced relative risk of each organ was weighted by its incidence rate in the German female population aged 50 years and older [24] , listed in Table S1 in the supplementary material. These incidence rates were chosen for their completeness including also rare cancer sites. European rates [25] are similar.
The afore-mentioned studies assumed the linear nothreshold (LNT) model:
Here, RR denotes the relative risk compared with an unexposed person, and the excess relative risk is given by the product of ERR pd , the excess relative risk per unit dose, and D, the mean organ dose. We adopted this model for all solid cancer sites. Leukaemia risk, however, deserves special treatment as there is evidence for a strong non-linear dose dependence [26, 27] . In this case, knowledge of the dose-volume histogram of the active bone marrow is necessary to derive risks. The skeleton was thus contoured in the whole-body CT, and sectioned in eight different compartments. Dose-volume histograms of each compartment were combined weighted by their active bone marrow con- BC breast cancer, 3D-CRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, MC Monte Carlo, TLD Thermoluminescence detector a Risk estimates in this study are only based on the whole-body MC-based calculations tent [28] , cf. Table S4 in the supplementary material. To infer the risks, a model linear at low doses and exponentially suppressed at high doses was preferred in a study of patients treated for cervical cancer [26] :
Here, D is the local dose in Gy and the integration is performed over the volume of the active bone marrow. For this dose-response relationship, the effect of radiation is maximal at about 10 Gy and decreases for higher doses. On the other hand, the leukaemia risk was observed to be compatible with the LNT in a study of patients with cancer of the uterine corpus [27] with ERRpd = 0.13 (95% CI: 0.04; 0.27) per Gy-at least when considering external beam therapy only. Therefore, we will present risk estimates for both models.
Similar to leukaemia, risks for soft-tissue, bone and skin cancers may be affected by high therapeutic as well as by lower doses. However, these risks are not discussed in this work, in particular owing to the associated large uncertainties in risk estimates.
In general, calculation of absolute risks depends on age, relative survival, and frequency of the outcome in the studied patient group. A rough estimate, however, is possible by multiplying excess relative risks with general population incidence rates (estimated absolute risk = excess relative risk × incidence rate; the incidence rates can be found in Table S1 in the supplementary material).
Different tangential techniques and inter-individual dose variability
In order to compare different tangential techniques, measurements were performed in an Alderson phantom with thermoluminescence detectors (Type 100-H, rods 1 × 6 mm), inserted at several positions in the trunk and the head of the phantom. With this approach, organ dose distributions cannot be calculated, but it is a reliable method for assessing differences between dose distributions of similar shapes.
The following techniques were investigated: first, the same field-in-field 3D-CRT without wedge compensation as studied with Monte Carlo calculations; second, the same technique but using external wedges; and third, a combination of manual and inverse planning was investigated, called 'hybrid IMRT' in the following. The hybrid IMRT was set up as a tangential technique where the main dose contribution (70-80%) is delivered by two open fields but dose homogeneity in the PTV is achieved by a number of segmented, inversely planned fields. All techniques were planned with the same main field angles. Plans were generated with Oncentra Masterplan 4.3, commissioned for the Siemens Primus (6 MV photon beams).
Finally, in order to obtain information on individual dose variation and the representativeness of our results, doses to some organs in the relative vicinity of the treated breast were compared with the PASSOS planning study. Details can be found at the end of the supplementary material. An overview of the different dosimetric approaches in this study is provided in Table 1 . and from [10] [11] [12] [13] . For comparison, the interquartile range of mean lung doses in modern radiotherapy is shown as determined by a review of the literature [4] . Details can be found in the main text. Circles denote IMRT techniques, squares are reserved for 3D-CRT without physical wedges and triangles for wedged 3D-CRT. When infomation on breast cancer laterality is available, markers for liver and stomach are shifted slightly in the corresponding direction. Overlying estimates were piled up. Note the logarithmic scale. 3D-CRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy
Results

Organ doses in 3D-CRT without wedges and multifield IMRT
Mean organ doses calculated by the Monte Carlo-based treatment planning system for the whole-body CT are depicted with black, solid symbols in Fig. 1 . The multi-field IMRT plan led to higher mean doses in all organs. For the ipsilateral lung, mean doses were 10 Gy for IMRT and 8 Gy for 3D-CRT. For the contralateral breast, the IMRT plan resulted in a rather high mean dose of 6 Gy. The other organs shown in Fig. 1 Table S5 of the supplementary material. For leukaemia, we apply a non-linear risk model. Therefore, a dose-volume histogram for the active bone marrow was derived, and shown in Fig. 2 . Since IMRT conforms more precisely to the PTV, the IMRT technique reduced the fraction of bone marrow with very high dose exposure. This reduction, however, applies only to a small volume (less than 1%) and is at the cost of higher doses to the major part of the bone marrow.
Cancer risks
Relative risks of secondary cancer, estimated for the wholebody CT from Monte Carlo calculations are shown in the upper part of Table 2 . For 3D-CRT, the relative risk was highest for lung cancer, with a value of about 1.4. For the IMRT plan, the relative risk was even higher for the contralateral breast, owing to the much higher dose compared with the 3D-CRT plan (Fig. 1) . For both plans, the nonlinear leukaemia model yielded a higher risk than the linear model but the two results were consistent within 90% confidence intervals. Most organs were aggregated (column "other") and their average estimated relative risk, weighted by the cancer incidence rates, was below 1.1. The aggregation was performed because single-organ risk uncertainties are large in particular for low doses (see 'Discussion'). Nevertheless, it might be interesting to state some additional risk estimates in order to understand the contribution of The first two rows show relative risks compared to an unexposed person, estimated in the present study from doses derived by Monte Carlo planning, for 3D-CRT without wedges and multi-field IMRT. The 90% confidence intervals were derived from the 90% or, by scaling, 95% confidence intervals of the risk coefficients and do not take into account other sources of uncertainty. The last row is adapted from [3] and shows the relative risks and 90% confidence intervals (scaled from standard errors) comparing women treated for breast cancer with and without radiotherapy 3D-CRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, LNT linear no-threshold, lin-exp linear-exponential different organs: For right-sided therapy, quite high relative risks of 1.2 for 3D-CRT without wedges and 1.4 for multifield IMRT were derived for the liver. However, as liver cancer is comparatively rare, the absolute contribution of liver cancer to the total risk is modest. Relatively frequent are cancers of the uterus and the colon. While the dose to the uterus was almost negligible in this study, inference of the colon dose yielded relative risks of 1.06 for the 3D-CRT and 1.1 for the IMRT plan. Similar relative risks were estimated for the stomach and pancreas.
Apart from leukaemia, all risk models applied in this study are linear in dose. Therefore, the higher mean doses from the IMRT technique led to higher risks compared with the 3D-CRT technique. According to the linear-exponential dose-response relationship for leukaemia risk, doses around 10 Gy are most detrimental. Compared with 3D-CRT, a larger fraction of active bone marrow was exposed to doses in this range for the IMRT plan (Fig. 2) , associated with a higher predicted risk ( Table 2) . 
Multi-field IMRT
In Fig. 3 the absolute risks based on the relative risks from Table 2 are shown. The best estimate for the number of radiation-induced cancers in remote organs was close to the number of radiation-induced lung cancer cases, in particular for IMRT. The number of excess cancers in remote organs may also be comparable to the number of excess contralateral BCs, which was, however, highly uncertain.
Comparing different tangential techniques
In order to evaluate the impact of variations in the 3D-CRT technique, a direct comparison of doses from different tangential techniques was made via thermoluminescence measurements in a phantom. Markers in Fig. 4 show the measured doses at various positions in the phantom including positions in the lung and the heart but also more remote ones such as the head and the abdomen. For each position, doses from the field-in-field 3D-CRT without wedges are plotted in the x-direction and doses from other techniques are plotted in the y-direction. The application of wedges increased the doses. The relative difference was highest for the lowest doses. For example, the dose as obtained from 3D-CRT with wedges was almost 0.5 Gy at a position where it was only 0.2 Gy when applying 3D-CRT without wedges. On the other hand, applying inverse planning with the same main tangents as in the 3D-CRT plan (hybrid IMRT) led to doses that were practically indistinguishable from the manual planning.
In order to check the independence of these results from the specific plan and anatomy used, we also show as lines data from the PASSOS patient planning study (see supplementary material). They refer to the group average of the dose-volume histograms of the parts of the patients' bodies covered by the planning CTs. The dose of each percentile of the dose-volume histogram for a given treatment technique is plotted against the same percentile for 3D-CRT without wedges. These data are imprecise at low doses (see 'Discussion'), but nevertheless do support the findings from the phantom measurements very well.
Discussion
Comparing the doses with the literature
Several publications have derived dose estimates for some organs for similar treatment techniques. Joosten et al. [11] performed an extensive Monte Carlo study evaluating, amongst others, a wedged 3D-CRT technique and a hybrid IMRT. The hybrid IMRT plan was based on the same tangent fields as the 3D-CRT technique but instead of wedges, two additional intensity-modulated tangent fields were applied. Donovan et al. [10] , Lee et al. [12] and Han et al. [13] determined the doses to some remote organs by measurements in a phantom. A field-in-field technique was used by Lee et al. and by Han et al. without physical wedges. The results of these studies are shown in Fig. 1 . Because in the study of Han et al. the field-in-field technique led to practically identical organ doses as an approach with enhanced dynamic wedges, we show only the former. Instead of mean organ doses, organ-equivalent doses are presented by Han et al. Organ-equivalent doses ( [29] ; not to be confused with the radiation protection concept of equivalent dose) correspond to a weighted dose metric with a relatively small contribution of high doses. They coincide with mean organ doses only in the limit of small doses. For example, the organ-equivalent dose to the liver as deduced from our IMRT data for right-sided radiotherapy reads 0.4 Gy to be compared with the mean liver dose of 1.2 Gy. For left-sided radiotherapy it reads 0.3 Gy, which is already closer to the mean dose of 0.5 Gy. Therefore, we do not present the data of Han et al. for organs close to the treated breast.
In general, our results agree with those from Joosten et al. and Han et al. The largest relative discrepancy was observed for the liver. However, such twofold differences can easily originate from inter-individual variation as can be seen for other organs from (Fig. 4) . Second, Joosten et al. investigated a hybrid IMRT. As illustrated in Fig. 4 , the choice for forward or inverse planning of sub-fields has practically no impact on remote doses as long as the dose is delivered by tangential fields. Therefore, doses from hybrid IMRT resemble doses from 3D-CRT without wedges.
On the other hand, Donovan et al. and Lee and al. provide mean doses to the ipsilateral lung that are exceedingly low. Both studies are based on thermoluminescence measurements in a phantom and thus cannot fully capture the dose gradient in the ipsilateral lung even with several detectors. In the study of Lee et al., the beams were directed through the phantom's breast without even touching the lung (Fig. 2 therein) . This was not feasible in any patient in the PASSOS planning study. In the study by Donovan et al., a relatively low prescribed dose of 40 Gy was applied K to the whole breast, contrary to 50.4 Gy in the present study that additionally involves boost irradiation. This difference, however, does not suffice to explain the low lung dose. Lung doses after different modern techniques of BC radiotherapy were extensively reviewed [4, 30] . Results from Donovan et al. and Lee et al. are about an order of magnitude below mean ipsilateral lung doses typical for modern radiotherapy [4] , plotted as grey rectangles in Fig. 1 . Ipsilateral lung doses below 1 Gy were observed only for partial breast irradiation [30] . On the contrary, our results for ipsilateral lung doses are well within the typical range. For the contralateral lung our estimates as well as the difference between tangential and IMRT technique are somewhat below values regarded as typical in the reviews [4, 30] .
Comparing estimated with observed relative risks
Many approaches to estimate secondary cancer risks after radiotherapy have been applied in the literature, and the results differ widely [15] . Therefore, it is important to check that results are consistent with the observed excess cases in large patient populations. Meta-analyses of various randomized trials on radiotherapy within the Early Breast Cancer Trialists' Collaborative Group comprise more than 30,000 patients [3] . Organ doses were not available in the meta-analysis. However, relative risks of radiotherapy versus no radiotherapy were derived and are largely consistent with our estimates (Table 2 ). Finally, it should be noted that the meta-analysis includes trials with outdated radiotherapy techniques that involve higher doses to organs-atrisk compared with contemporary techniques. Higher doses may have resulted from extended target volumes, or from older irradiation facilities. Moreover, application of wedges leads to higher exposure far from the main fields (Fig. 4) . Indeed, our estimates for 3D-CRT without wedges tend to be below estimates from the meta-analysis.
Limitations
Uncertainties are substantial with regard to many results in the present manuscript. To reduce uncertainty in the dose calculations, we applied a Monte Carlo-based algorithm. This algorithm proved to be accurate within about 30% even far from the field, at least when irradiating with a 10 × 10-cm 2 open field. Furthermore, individual anatomy is an important factor. Individual organ doses can deviate from the median of a patient cohort by more than a factor of two in both directions (see Fig. S7 in the supplementary material). Moreover, there is variation due to different LINAC geometries [31] , and there is variation related to the individual creation of the treatment plans. Nevertheless, dose estimates for remote organs roughly agree with other studies (Fig. 1) and respective explanations in the present discussion.
For estimation of the risk of second primary cancers, two additional major sources of uncertainty are involved. First, statistical uncertainty limits the precision of parameters in the risk models. Second, it is unclear how the risks compare between different cohorts and exposure scenarios. For the lung, breast and oesophagus, risk estimates exist from both BC patients and atomic bomb survivors, and although statistical uncertainty is large especially for the BC patients, it is apparent that BC patients show considerably lower risks per unit dose [20] [21] [22] [23] 32] . A possible explanation is the strong dose inhomogeneity in BC therapy [33] . Dose gradients in remote organs are less strong and mean organ doses are close to or below the mean body dose. In this case, cancer risks derived from the uniform exposure in atomic bomb survivors may be adopted to calculate risks in remote organs in BC radiotherapy. To cover both the atomic bomb survivor data and, for higher doses, the therapeutic risk data, non-linear models have been proposed [29, 34, 35] . These models assume that risk coefficients derived from the atomic bomb survivors can be applied to the lowdose regimen and a flattening of risk for high doses is imposed in order to be compatible with the results from radiotherapy studies. However, so far, no single epidemiological study could provide evidence in favour of a flattening or downturn of lung cancer or BC risk for high doses [36] . To mitigate this problem, we applied risk coefficients derived in studies on BC patients for some organs close to the treated breast. Even though radiotherapy has evolved during the past decades, these studies yield the best approximation of the dose distribution in the body in contemporary BC radiotherapy, and dependence of risk estimates on the possible non-linearity of the dose-response relationship is thus alleviated. A comparison of linear and non-linear risk models for lung cancer risk was carried out [37] and the nonlinear models were reported to overestimate absolute risks. Finally, it should be noted that a flattening or downturn of the dose response for high doses would strengthen the relative importance of the low-dose region. On the other hand, applying results from diverse studies, there may be some variation in risk estimates owing to different study designs and populations.
On the impact of the cancer risk in remote organs
While relative risks are preferable for comparing different studies, absolute risk estimates are more instructive for rating the impact. Rough estimates of absolute risks were derived in Fig. 3 by multiplication of relative risks with general population incidence data. For this approach to be valid it is important to note that the risk for cancer in organs other than the breast is similar in BC patients not treated with radiotherapy and the general population [38] . Regarding the risk of contralateral BC, BC patients were under increased risk in the past but introduction of tamoxifen has approximately halved the number of contralateral BCs, which are now close to or even below the population average [39, 40] .
In the meta-analysis of randomized trials [3] , an estimated number of 39 radiation-induced cancers in remote organs occurred during about 130,000 years of follow-up. Although associated with large uncertainties, this number is highly compatible with our rough estimate (Fig. 3) . Consistent with our estimates in Fig. 3 , a similar number of lung cancers (49) was attributed to radiotherapy in the meta-analysis, and only 15 cases of leukaemia. In view of the strong association of lung cancer risk with smoking behaviour [4, 37] , the agreement is even better than expected. About 114 cases of contralateral BC were attributed to radiotherapy. However, in most studies included in the meta-analysis, tamoxifen was not administered to the patients. Therefore, for contemporary treatment schemes, radiation-induced risk for contralateral BC may be of very similar magnitude to the radiation-induced risk in more remote organs.
Although the afore-mentioned radiation-induced risks are not very large, they represent a sizeable contribution to the risk-benefit ratio of radiotherapy: For women with a 5-year local recurrence risk above 10%, adjuvant radiotherapy lowers the risk of BC death by 5% during 15 years after treatment [3] . On the other hand, our estimates imply a risk for radiation-induced incidence of cancer of the lung, contralateral breast, remote organs, and leukaemia for 3D-CRT (IMRT) of about 80 (180) cases in 100,000 years ( Fig. 3) , which means about 1.2% (2.7%) within 15 years.
Conclusion
While the risk of radiation-induced cancer was estimated directly from studies of BC therapy for organs in the relative vicinity of the treated breast, this was not possible for remote organs. When applying risk coefficients derived from the atomic bomb survivors for other organs, the estimated absolute number of radiation-induced cancers in more remote organs was of comparable magnitude to the estimated number of radiation-induced lung cancers or contralateral BCs. A reduction of peripheral exposure could be achieved by tangential irradiation without external wedges. The same method also led to the lowest exposure of organs close to the treated breast such as the lungs or contralateral breast, and is thus preferable regarding radiation-induced cancer risk.
